口服普萘洛尔治疗婴儿血管瘤的近期和远期安全性

doi:10.3760/cma.j.issn.0412-4030.2019.08.019

Abstract

Abstract: 【Abstract】 Infantile hemangioma is the most common tumor in infancy, with an incidence of 4% - 5%. According to the risk level, hemangioma is divided into 3 levels: high risk, medium risk and low risk. At present, the first-line treatment of high-risk hemangioma is oral propranolol （β-receptor blockers）. It has been 10 years since infantile hemangioma was treated with propranolol for the first time, and propranolol has been the drug of first-choice in systematic treatment due to its high efficacy and good safety, but its long-term adverse effect needs further evaluation.

Key words: Hemangioma, Propranolol, Infant, Long?term safety, Short?term safety

Yu Lu, Li Li, Ma Lin. Short- and long-term safety of oral propranolol in the treatment of infantile hemangioma[J].Chinese Journal of Dermatology, 2019, 52(8): 586-589.

References ［41］

［1］	Kilcline C, Frieden IJ. Infantile hemangiomas: how common are they? A systematic review of the medical literature［J］. Pediatr Dermatol, 2008,25（2）:168⁃173. doi: 10.1111/j.1525⁃1470.2008. 00626.x.
［2］	Léauté⁃Labrèze C, Hoeger P, Mazereeuw⁃Hautier J, et al. A randomized, controlled trial of oral propranolol in infantile hemangioma［J］. N Engl J Med, 2015,372（8）:735⁃746. doi: 10.1056/NEJMoa1404710.
［3］	杨舟, 李丽, 徐子刚, 等. 普萘洛尔治疗婴儿血管瘤的临床疗效及安全性［J］. 中华皮肤科杂志, 2012,45（7）:466⁃469. doi: 10.3760/cma.j.issn.0412⁃4030.2012.07.003.
［4］	Shehata N, Powell J, Dubois J, et al. Late rebound of infantile hemangioma after cessation of oral propranolol［J］. Pediatr Dermatol, 2013,30（5）:587⁃591. doi: 10.1111/pde.12190.
［5］	Chu DH, Castelo⁃Soccio L, Wan J, et al. Retrospective analysis of beta⁃blocker instituted for treatment of hemangiomas （RABBIT study）［J］. Clin Pediatr （Phila）, 2014,53（11）:1084⁃1090. doi: 10.1177/0009922814535660.
［6］	Chang L, Gu Y, Yu Z, et al. When to stop propranolol for infantile hemangioma［J］. Sci Rep, 2017,7:43292. doi: 10.1038/srep43292.
［7］	马琳. 儿童皮肤病学［M］. 北京：人民卫生出版社, 2014:143⁃164.
［8］	Csoma ZR, Dalmády S, Ábrahám R, et al. Infantile haemangioma: clinical and demographic characteristics, experiences in the treatment［J］. Orv Hetil, 2017,158（39）:1535⁃1544. doi: 10.1556/ 650.2017.30838.
［9］	Xue L, Sun C, Xu DP, et al. Clinical outcomes of infants with periorbital hemangiomas treated with oral propranolol［J］. J Oral Maxillofac Surg, 2016,74（11）:2193⁃2199. doi: 10.1016/j.joms. 2016.04.021.
［10］	Léaute⁃Labrèze C, Boccara O, Degrugillier⁃Chopinet C, et al. Safety of oral propranolol for the treatment of infantile hemangioma: a systematic review［J］. Pediatrics, 2016,138（4）. pii: e20160353. doi: 10.1542/peds.2016⁃0353.
［11］	Stringari G, Barbato G, Zanzucchi M, et al. Propranolol treatment for infantile hemangioma: a case series of sixty⁃two patients［J］. Pediatr Med Chir, 2016,38（2）:113. doi: 10.4081/pmc.2016.113.
［12］	Techasatian L, Komwilaisak P, Panombualert S, et al. Propranolol was effective in treating cutaneous infantile haemangiomas in Thai children［J］. Acta Paediatr, 2016,105（6）:e257⁃e262. doi: 10.1111/apa.13378.
［13］	Furuta S, Sato H, Tsuji S, et al. Effective treatment for infantile hemangioma with long⁃pulsed dye laser with oral propranolol medication: a preliminary report［J］. Pediatr Surg Int, 2016,32（9）:857⁃862. doi: 10.1007/s00383⁃016⁃3942⁃x.
［14］	杨宝峰, 陈建国. 药理学［M］. 第3版. 北京: 人民卫生出版社, 2015:103⁃111.
［15］	Petrovic J, Trifunovic B, Vukomanovic G, et al. Oral propranolol for infantile hemangiomas: a prospective study on the role of 48⁃hour Holter monitoring in additional safety assessment［J］. J Dermatolog Treat, 2017,28（6）:554⁃558. doi: 10.1080/09546634. 2016.1277177.
［16］	Salice P, Giovanni BM, Giavarini A, et al. Cardiovascular profile of propranolol after multiple dosing in infantile hemangioma［J］. Pharmacology, 2017,99（1⁃2）:75⁃78. doi: 10.1159/000450755.
［17］	易兰芬, 文红霞, 黄穗, 等. 婴幼儿血管瘤患者口服小剂量普萘洛尔前后动态心电图的比较［J］. 中国当代儿科杂志, 2016,18（4）:345⁃349. doi: 10.7499/j.issn.1008⁃8830.2016.04.013.
［18］	de Graaf M, JMPJ B, Raphaël MF, et al. Adverse effects of propranolol when used in the treatment of hemangiomas: a case series of 28 infants［J］. J Am Acad Dermatol, 2011,65（2）:320⁃327. doi: 10.1016/j.jaad.2010.06.048.
［19］	Puttgen KB, Summerer B, Schneider J, et al. Cardiovascular and blood glucose parameters in infants during propranolol initiation for treatment of symptomatic infantile hemangiomas［J］. Ann Otol Rhinol Laryngol, 2013,122（9）:550⁃554. doi: 10.1177/00034 8941312200903.
［20］	Mei⁃Zahav M, Blau H, Hoshen M, et al. Propranolol treatment for infantile hemangioma does not increase risk of childhood wheezing［J］. Pediatr Pulmonol, 2017,52（8）:1071⁃1075. doi: 10. 1002/ppul.23683.
［21］	van Veen MR, van Hasselt PM, de Sain⁃van der Velden MG, et al. Metabolic profiles in children during fasting［J］. Pediatrics, 2011,127（4）:e1021⁃e1027. doi: 10.1542/peds.2010⁃1706.
［22］	Yang TB, McMahon P, De Léon DD, et al. Use of propranolol for treating hemangiomas in infants with previously diagnosed hypoglycemic conditions［J］. Pediatr Dermatol, 2016,33（6）:e381⁃e384. doi: 10.1111/pde.12975.
［23］	Cavalli R, Buffon RB, de Souza M, et al. Tumor lysis syndrome after propranolol therapy in ulcerative infantile hemangioma: rare complication or incidental finding?［J］. Dermatology, 2012,224（2）:106⁃109. doi: 10.1159/000337553.
［24］	Pavlakovic H, Kietz S, Lauerer P, et al. Hyperkalemia complicating propranolol treatment of an infantile hemangioma［J］. Pediatrics, 2010,126（6）:e1589⁃e1593. doi: 10.1542/peds. 2010⁃0077.
［25］	Wang C, Wang Q, Xiang B, et al. Effects of propranolol on neurodevelopmental outcomes in patients with infantile hemangioma: a case⁃control study［J］. Biomed Res Int, 2018,2018:5821369. doi: 10.1155/2018/5821369.
［26］	刘卫平. 探讨口服普萘洛尔治疗婴幼儿血管瘤对生长发育的影响［J］. 中国医疗美容, 2016,6（11）:54⁃56. doi: 10.3969/j.issn.2095⁃0721.2016.11.026.
［27］	Phillips RJ, Penington AJ, Bekhor PS, et al. Use of propranolol for treatment of infantile haemangiomas in an outpatient setting［J］. J Paediatr Child Health, 2012,48（10）:902⁃906. doi: 10. 1111/j.1440⁃1754.2012.02521.x.
［28］	Fernando SJ, Leitenberger S, Majerus M, et al. Use of intravenous propranolol for control of a large cervicofacial hemangioma in a critically ill neonate［J］. Int J Pediatr Otorhinolaryngol, 2016,84:52⁃54. doi: 10.1016/j.ijporl.2016.02.005.
［29］	Kado M, Shimizu A, Matsumura T, et al. Successful treatment of infantile hemangiomas with propranolol in low⁃birth⁃weight infants［J］. J Craniofac Surg, 2017,28（3）:789⁃793. doi: 10.1097/SCS.0000000000003542.
［30］	Vergine G, Marsciani A, Pedini A, et al. Efficacy of propranolol treatment in thyroid dysfunction associated with severe infantile hepatic hemangioma［J］. Horm Res Paediatr, 2012,78（4）:256⁃260. doi: 10.1159/000337253.
［31］	桂永浩, 薛辛东. 儿科学［M］. 3版. 北京：人民卫生出版社, 2015:364⁃365.
［32］	González⁃Llorente N, Del OI, Muñoz⁃Ollero N, et al. Study of cognitive function in children treated with propranolol for infantile hemangioma［J］. Pediatr Dermatol, 2017,34（5）:554⁃558. doi: 10.1111/pde.13229.
［33］	Gonski K, Wargon O. Retrospective follow up of gross motor development in children using propranolol for treatment of infantile haemangioma at Sydney Children′s Hospital［J］. Australas J Dermatol, 2014,55（3）:209⁃211. doi: 10.1111/ajd. 12156.
［34］	Moyakine AV, Hermans DJ, Fuijkschot J, et al. Propranolol treatment of infantile hemangiomas does not negatively affect psychomotor development［J］. J Am Acad Dermatol, 2015,73（2）:341⁃342. doi: 10.1016/j.jaad.2015.04.053.
［35］	董建勇, 李凯, 岳琳琳, 等. 口服普萘洛尔对血管瘤患儿体格发育的近期影响［J］. 中国口腔颌面外科杂志, 2016,14（6）:510⁃513.
［36］	吴凡. 普萘洛尔治疗婴幼儿血管瘤的临床疗效和对神经系统发育影响的评估［D］. 济南: 山东大学, 2016.
［37］	Moyakine AV, Kerstjens JM, Spillekom⁃van KS, et al. Propranolol treatment of infantile hemangioma （IH） is not associated with developmental risk or growth impairment at age 4 years［J］. J Am Acad Dermatol, 2016,75（1）:59⁃63.e1. doi: 10.1016/j.jaad. 2016.02.1218.
［38］	Hu L, Zhou B, Huang H, et al. Effects of systemic propranolol treatment on physical growth of patients with infantile hemangiomas［J］. J Dermatol, 2016,43（10）:1160⁃1166. doi: 10. 1111/1346⁃8138.13324.
［39］	Steenen SA, van Wijk AJ, van der Heijden GJ, et al. Propranolol for the treatment of anxiety disorders: Systematic review and meta⁃analysis［J］. J Psychopharmacol, 2016,30（2）:128⁃139. doi: 10.1177/0269881115612236.
［40］	Moyakine AV, Spillekom⁃van KS, van der Vleuten CJM. Propranolol treatment of infantile hemangioma is not associated with psychological problems at 7 years of age［J］. J Am Acad Dermatol, 2017,77（1）:105⁃108. doi: 10.1016/j.jaad.2017.01.025.
［41］	Castaneda S, Melendez⁃Lopez S, Garcia E, et al. The role of the pharmacist in the treatment of patients with infantile hemangioma using propranolol［J］. Adv Ther, 2016,33（10）:1831⁃1839. doi: 10.1007/s12325⁃016⁃0391⁃9.

[1]	Lin Yangyang, Gong Zekun, Zhao Li , Li Qinfeng. Seven cases of infant lichen scrofulosorum related to bacillus Calmette-Guérin vaccination [J]. Chinese Journal of Dermatology, 2019, 52(8): 533-536.
[2]	Shen Chunping, Wang Hua, Wang Liuhui, Xiao Yuanyuan, Ma Lin. Comparison of desonide 0.05% cream versus hydrocortisone butyrate cream in the treatment of infantile atopic dermatitis: a multicenter, randomized, parallel-group, controlled clinical study [J]. Chinese Journal of Dermatology, 2019, 52(1): 11-15.
[3]	Xiao Yuanyuan, Xu Zigang, Xu Zhe, Xiang Xin, Liu Ying, Ma Lin, Yang Zhou. Vincristine combined with glucocorticoids for the treatment of 11 cases of infantile Kasabach-Merritt syndrome [J]. Chinese Journal of Dermatology, 2018, 51(8): 601-603.
[4]	Qing-wei Geng Wang-Min. Clinicopathological analysis of 22 cases of cutaneous epithelioid hemangioma [J]. Chinese Journal of Dermatology, 2018, 51(6): 459-462.
[5]	Ye Wenxia, Jin Wanwan, Quan Hehe, Fang Shan, Xue Ximao, Tong Yi, Lu Shujiao, Gao Yu. Safety and efficacy of 595-nm pulsed dye laser combined with topical timolol maleate 0.5% solution for the treatment of superficial infantile hemangioma [J]. Chinese Journal of Dermatology, 2018, 51(12): 888-892.
[6]	. Efficacy and safety of Chushizhiyang ointment for the treatment of mild atopic dermatitis in infants: a multicenter clinical study [J]. Chinese Journal of Dermatology, 2017, 50(4): 279-282.
[7]	. Cutaneous and visceral hemangiomas in an infant [J]. Chinese Journal of Dermatology, 2015, 48(4): 284-284.
[8]	. Curcumin for propranolol-induced psoriasis-like lesions in guinea pigs: evaluation of therapeutic efficacy and effects on proliferating cell nuclear antigen expression [J]. Chinese Journal of Dermatology, 2015, 48(3): 175-178.
[9]	. Efficacy and safety of propranolol in treating infantile hemangiomas [J]. Chinese Journal of Dermatology, 2012, 45(7): 466-469.
[10]	. A case of targetoid hemosiderotic hemangioma [J]. Chinese Journal of Dermatology, 2010, 43(7): 516-516.
[11]	. Therapeutic efficacy of 1064 nm long-pulsed tunable Nd:YAG laser on 196 cases of hemangioma [J]. Chinese Journal of Dermatology, 2009, 42(3): 206-207.
[12]	. Therapeutic efficacy of long-pulsed tunable Nd:YAG laser on capillary hemangioma [J]. Chinese Journal of Dermatology, 2009, 42(2): 88-90.
[13]	LIN Neng-xing, LIAN Xin, Kazunori Urabe, Masutaka Furue, TU Ya-ting. Expressions of phosphorylated Stat3, Akt and cyclin D1 in angiosarcoma [J]. Chinese Journal of Dermatology, 2007, 40(3): 155-157.
[14]	CHEN Zheng, RAN Yu-ping, XIONG Lin, DAI Ya-lin, ZHOU Guang-ping. A prospective study on skin colonization by Malassezia in neonates [J]. Chinese Journal of Dermatology, 2006, 39(7): 371-373.
[15]	LIU Juan, SHAN Sheng-guo, ZHANG Duan-lian, YU Ying, YANG Yong. Expression of p63 and p73 Protein in Capillary Hemangioma [J]. Chinese Journal of Dermatology, 2005, 38(2): 89-91.

Short- and long-term safety of oral propranolol in the treatment of infantile hemangioma

PDF

Like

Knowledge

Abstract

Cite this article

share this article

References ［41］

Related Articles 15

Metrics

Comments

Recommended 10